Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.
Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.
复制标题
DOI：
10.1016/j.clbc.2017.12.006
复制
发表时间：
2018-10
影响因子：
3.1
通讯作者：
Li X
中科院分区：
文献类型：
--
作者：
Meisel J;Zhang C;Neely C;Mendoza P;You S;Han T;Liu Y;Sahin AA;O'Regan R;Li X
1-10组和11-18组患者预后良好。那些经历过复发的人更有可能是绝经前的，并且未能遵守推荐的内分泌治疗方案。在这些患者中，内分泌治疗仍然很重要。激素受体阳性/人表皮生长因子受体2 （HER2）阴性无淋巴结转移的乳腺癌预后良好。我们比较了激素受体阳性、her2阴性、淋巴结阴性肿瘤的预后，Oncotype DX评分范围为1 ~ 10（1 - 10组）和11 ~ < 18（11 - 18组）。1-10组共107例，11-18组共225例。所有患者均接受手术治疗。比较两组患者化疗、放疗和内分泌治疗的使用情况，以及总生存期（OS）、无病生存期（DFS）和远处转移。1-10组与11-18组化疗（5.05% vs. 6.05%, P = .724）和放疗（52.53% vs. 59.07%, P = .276）使用情况比较，差异均无统计学意义。1 ~ 10组的中位OS和DFS分别为47和45个月，11 ~ 18组的中位OS和DFS分别为49和48个月。OS （P = 0.995）、DFS （P = 0.148）和转移率（P = 0.998）无统计学差异。11-18组死亡和远处转移（死亡5例，复发2例，转移2例）多于1-10组（死亡0例，复发4例，转移0例）。在两组中，大多数复发患者都是未能遵守内分泌治疗方案的年轻患者。1-10组和11-18组患者预后良好。那些经历过复发的人更有可能是绝经前的，并且未能遵守推荐的内分泌治疗方案。在这些患者中，内分泌治疗仍然很重要。
Patients in both the 1–10 group and the 11–18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients. Hormone receptor–positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor–positive, HER2-negative, lymph node–negative cancers with Oncotype DX score ranges of 1 to 10 (1–10 group) and 11 to < 18 (11–18 group). A total of 107 cases in the 1–10 group and 225 cases in the 11–18 group were reviewed. All patients received surgery. The use of chemotherapy, radiotherapy, and endocrine therapy, and overall survival (OS), disease-free survival (DFS), and distant metastasis were compared between groups. There were no statistical differences in the use of chemotherapy (5.05% vs. 6.05%, P = .724) or radiotherapy (52.53% vs. 59.07%, P = .276) between the 1–10 group and the 11–18 group, respectively. The median OS and DFS were 47 and 45 months, respectively, in the 1 −10 group, and 49 and 48 months in the 11–18 group. No significant difference was seen in OS (P = .995), DFS (P = .148), or rates of metastasis (P = .998). The 11–18 group had more death events and distant metastasis (death, 5 events; recurrence, 2 events; metastasis, 2 events) than the 1–10 group (death, 0 events; recurrence, 4 events; metastasis, 0 events). The majority of recurrences seen in both groups were in young patients who failed to comply with their endocrine therapy regimen. Patients in both the 1–10 group and the 11–18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients.
登录
查看更多内容
DOI：
10.1093/jnci/djv048
发表时间：
2015-06
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Kohler BA;Sherman RL;Howlader N;Jemal A;Ryerson AB;Henry KA;Boscoe FP;Cronin KA;Lake A;Noone AM;Henley SJ;Eheman CR;Anderson RN;Penberthy L
通讯作者：
Penberthy L
DOI：
10.1056/nejmoa1510764
发表时间：
2015-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sparano JA;Gray RJ;Makower DF;Pritchard KI;Albain KS;Hayes DF;Geyer CE Jr;Dees EC;Perez EA;Olson JA Jr;Zujewski J;Lively T;Badve SS;Saphner TJ;Wagner LI;Whelan TJ;Ellis MJ;Paik S;Wood WC;Ravdin P;Keane MM;Gomez Moreno HL;Reddy PS;Goggins TF;Mayer IA;Brufsky AM;Toppmeyer DL;Kaklamani VG;Atkins JN;Berenberg JL;Sledge GW
通讯作者：
Sledge GW
影响因子：
4.6
作者：
Ogden A;Garlapati C;Li XB;Turaga RC;Oprea-Ilies G;Wright N;Bhattarai S;Mittal K;Wetherilt CS;Krishnamurti U;Reid MD;Jones M;Gupta M;Osan R;Pattni S;Riaz A;Klimov S;Rao A;Cantuaria G;Rida PC;Aneja R
通讯作者：
Aneja R
影响因子：
3.5
作者：
Li, Xiaoxian Bill;Krishnamurti, Uma;Aneja, Ritu
通讯作者：
Aneja, Ritu
影响因子：
254.7
作者：
Siegel, Rebecca;Ma, Jiemin;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin